Perdrix, A.; Najem, A.; Saussez, S.; Awada, A.; Journe, F.; Ghanem, G.; Krayem, M.
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers 2017, 9, 172.
https://doi.org/10.3390/cancers9120172
AMA Style
Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M.
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers. 2017; 9(12):172.
https://doi.org/10.3390/cancers9120172
Chicago/Turabian Style
Perdrix, Anne, Ahmad Najem, Sven Saussez, Ahmad Awada, Fabrice Journe, Ghanem Ghanem, and Mohammad Krayem.
2017. "PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies" Cancers 9, no. 12: 172.
https://doi.org/10.3390/cancers9120172
APA Style
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M.
(2017). PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers, 9(12), 172.
https://doi.org/10.3390/cancers9120172